Option chain shows key data for BiomX's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for BiomX.

BiomX (AMEX:PHGE) Stock, Option Chain

BIOMX INC

BiomX

BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.

Wall-Street-ai5

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

DXCM

PHGE

Top 3 Health Care Stocks That May Explode In Q3

Pharmaceuticals therapeutics

Penny Stocks

Movers

BiomX shares are trading higher Wednesday after the company announced it has entered into a definitive merger agreement with Adaptive Phage Therapeutics, Inc. The acquisition is expected to close within the next 30 days, subject to the satisfaction of the closing conditions.

Why BiomX Stock Is Surging Today

Small Cap

Intraday Update

ATXI

AULT

BDRX

BILI

BIVI

BMEA

CCRD

Envoy Medical, Inc. - Class A Common Stock

COCH

CPHI

CRWD

CVNA

DERM

EGRX

ESGL

FLNC

FTCH

HNRA

LESL

NTAP

OKTA

PDCO

RDHL

ROVR

SEEL

VCXA

VERV

VTVT

VVOS

WDAY

WOOF

YOSH

Shares of Patterson Companies, Inc. (NASDAQ: PDCO) moved lower during Wednesday’s session after the company reported worse-than-expected second-quarter financial results and lowered FY24 adjusted EPS guidance below estimates.

Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

BiomX Inc

BiomX Inc Warrants (13/12/2023)

Press Releases

BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference

BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

BiomX Announces a Mandatory Unit Separation

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

Earnings

BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards

Financing

BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

BioCardia

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Elevation Oncology

Equillium

GlycoMimetics

HCW Biologics

HOOKIPA Pharma

Imunon

IN8bio

Kairos Pharma

Leap Therapeutics

Moleculin Biotech

MEI Pharma

Marker Therapeutics

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

Portage Biotech

Palatin Techs

SAB Biotherapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Synlogic

HC Wainwright & Co.

Laidlaw & Co.

Chardan Capital

Ladenburg Thalmann

WIIM

BiomX shares are trading lower after the company reported Phase 2 results for BX211.

Comments

BiomX

BiomX (PHGE) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga